Guardian Pharmacy Services, Inc. (GRDN) P/E Ratio History
Fairly ValuedTrading at 40.1x, near 5Y avg of 40.2x · 40th percentile · In line with own history · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of November 21, 2026, Guardian Pharmacy Services, Inc. (GRDN) trades at a price-to-earnings ratio of 40.1x, with a stock price of $46.94 and trailing twelve-month earnings per share of $1.17.
The current P/E is roughly in line with its 5-year average of 40.2x. Over the past five years, GRDN's P/E has ranged from a low of 34.9x to a high of 45.4x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.4x, GRDN trades at a 65% premium to its sector peers. The sector includes 249 companies with P/E ratios ranging from 0.0x to 185.4x.
The PEG ratio of 2.14 (P/E divided by 144% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, GRDN commands a significant premium over the S&P 500 median P/E of 20.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GRDN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GRDN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GRDN P/E vs Peers
Drug Distributors & Pharmacies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 33.8 | - | -84% | |
| $103B | 9.4Lowest | - | -62% | |
| $125B | 26.6 | - | +49%Best | |
| $64B | 35.0 | 1.24 | +12% | |
| $43B | 43.3 | 2.38 | +26% | |
| $10B | 26.2 | 1.90 | +14% | |
| $2B | 20.5 | 1.02Best | +23% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GRDN Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $40.78 | $1.17 | 34.9x | -13% |
| FY2026 Q2 | - | $41.87 | $1.03 | 40.7x | +1% |
| FY2026 Q1 | - | $37.66 | $0.83 | 45.4x | +13% |
| FY2025 Q4 | Dec 31 2025 | $30.09 | $0.77 | 39.1x | -3% |
| FY2025 Q3 | - | $26.23 | $0.64 | 41.0x | +2% |
Average P/E for displayed period: 40.2x
GRDN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GRDN — Frequently Asked Questions
Quick answers to the most common questions about buying GRDN stock.
What is GRDN's P/E ratio?
Guardian Pharmacy Services, Inc. (GRDN) trailing twelve-month P/E ratio is 40.1x, based on TTM diluted EPS of $1.17. The 5-year average P/E is 40.2x and the historical range spans 34.9x to 45.4x.
Is GRDN stock overvalued or undervalued?
GRDN trades at 40.1x P/E, near its 5-year average of 40.2x. The 40th percentile ranking within the 34.9x–45.4x historical range places valuation within normal bounds.
Is GRDN stock expensive?
GRDN is fairly valued relative to its own history. The current P/E of 40.1x is near the 5-year average of 40.2x (40th percentile of historical range).
What is GRDN's historical P/E range?
Over the past 5 years, GRDN's P/E ratio has ranged from 34.9x to 45.4x, with a median of 40.7x and an average of 40.2x. The current P/E of 40.1x places the stock at the 40th percentile of this range. Full historical data spans 2025–2026.
How does GRDN's P/E compare to the S&P 500?
GRDN trades at 40.1x P/E versus the S&P 500 median of 20.9x. The 92% premium to the market typically reflects higher expected earnings growth or quality.
How does GRDN's valuation compare to Healthcare peers?
Guardian Pharmacy Services, Inc. P/E of 40.1x compares to the Healthcare sector median of 24.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GRDN's PEG ratio?
GRDN PEG ratio is 2.14, based on a P/E of 40.1x and EPS growth of 144.1%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is GRDN's earnings yield?
GRDN earnings yield is 2.49%, the inverse of its 40.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.